Document is current
Any future updates will be listed below
-
Authors
Mallardo, Domenico https://orcid.org/0000-0002-1081-5313
Simeone, Ester https://orcid.org/0000-0003-2964-0434
Festino, Lucia https://orcid.org/0000-0002-3035-266X
Tuffanelli, Marilena https://orcid.org/0000-0002-2529-5808
Vanella, Vito https://orcid.org/0000-0002-1276-5516
Trojaniello, Claudia https://orcid.org/0000-0002-5677-5679
Vitale, Maria Grazia https://orcid.org/0000-0003-2331-5315
Ottaviano, Margaret https://orcid.org/0000-0001-9589-0808
Capone, Mariaelena https://orcid.org/0000-0002-1352-2532
Madonna, Gabriele https://orcid.org/0000-0001-9395-3190
Sparano, Francesca
Cioli, Eleonora https://orcid.org/0000-0002-8788-6574
Scarpato, Luigi https://orcid.org/0000-0003-2748-786X
Palla, Marco https://orcid.org/0000-0001-8901-0974
Di Trolio, Rossella https://orcid.org/0000-0003-1215-2602
Meinardi, Paolo https://orcid.org/0000-0002-2790-2296
Caracò, Corrado https://orcid.org/0000-0002-7828-079X
Ferrara, Gerardo
Muto, Paolo https://orcid.org/0000-0002-7546-6441
Cavalcanti, Ernesta https://orcid.org/0000-0001-6302-1579
Ascierto, Paolo Antonio https://orcid.org/0000-0002-8322-475X
-
Funding
Funding for this research was provided by:
Italian Ministry of Health
- License Information
-
More Information
Article History
Received: 12 December 2022
Accepted: 5 February 2023
First Online: 23 February 2023
Change Date: 19 May 2023
Change Type: Update
Change Details: Missing accessibility link in the backmatter.
Declarations
:
: This study was approved by the Ethics Committee of National Cancer Institute—IRCCS—Fondazione ‘‘G. Pascale’’, Naples, Italy, protocol number 32/22 oss. All patients provided their written informed consent to participate in this study.
: Consent to the data publication was given by patients.
: PAA has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi. AC received grant consultancies from BMS, Astrazeneca, Roche and MSD. He also received speaker's fee from Astrazeneca, Novartis and Eisai.
